A highly mutated COVID-19 variant, nicknamed “Cicada,” is now under close observation by global and U.S. health officials. First quietly circulating for an extended period, the Cicada (BA.3.2) variant has emerged in a growing number of regions, detected in at least 25 U.S. states and over 23 countries worldwide. While not yet causing widespread severe disease, its unique genetic profile raises questions about potential immune evasion. This comprehensive report details everything you need to know about BA.3.2, its spread, symptoms, and what experts are saying about its implications for public health.
What is the Cicada (BA.3.2) COVID Variant?
The Cicada variant is the nickname given to BA.3.2, a distinct lineage of SARS-CoV-2. It earned its moniker from evolutionary biologist T. Ryan Gregory, who compared its slow, “underground” emergence to the cicada insect. For years, this variant largely flew under the radar before its recent uptick in detection. Health officials now monitor it closely because of its significant genetic changes.
BA.3.2 is a descendant of the Omicron subvariant BA.3, which first appeared in 2022. It was initially identified in South Africa in November 2024. After a period of limited circulation, cases began to increase globally in September 2025. The World Health Organization (WHO) formally classified BA.3.2 as a “variant under monitoring” in December 2025 due to its unique characteristics, highlighting the need for ongoing surveillance. The Centers for Disease Control and Prevention (CDC) started tracking it officially by March 19, 2026.
Understanding Cicada’s Unique Mutations
What makes the Cicada variant particularly noteworthy is its extensive genetic makeup. Dr. Robert H. Hopkins Jr., medical director of the National Foundation for Infectious Diseases, notes that BA.3.2 possesses a staggering 70 to 75 mutations in its spike protein. This significant number of changes distinguishes it sharply from other circulating strains, including the JN.1 lineage that has predominantly caused U.S. infections over the last two years.
These mutations create a “genetically distinct” lineage, meaning the virus may present differently to the human immune system. Virologist Andrew Pekosz from Johns Hopkins explains that these changes could potentially reduce the effectiveness of existing immune protection from prior infections or vaccinations. Laboratory studies cited by the CDC support this, indicating BA.3.2’s capacity to evade COVID-19 antibodies. However, some mutations might also inadvertently make the virus bind less effectively to human cells, creating a complex picture for its overall impact.
How is the Cicada Variant Spreading in the U.S.?
The Cicada COVID variant first entered the U.S. via a traveler from abroad in June 2025. The first case in a U.S. patient was diagnosed in January (likely 2026, given the timeline). Since then, its presence has been confirmed across numerous states, primarily through advanced surveillance methods.
Between January and February 11, 2026, the variant was detected in wastewater samples from 132 sites across at least 25 U.S. states. This robust wastewater monitoring system, a joint effort by the CDC’s National Wastewater Surveillance System and Stanford University’s WastewaterSCAN Dashboard, offers a reliable way to track pathogen circulation within communities, even when individual case reporting is low. Additionally, the variant has been found in voluntary nose swabs from international travelers.
States Reporting BA.3.2 Detection
The 25 states where the BA.3.2 variant has been detected through wastewater surveillance and other means include:
California
Connecticut
Florida
Hawaii
Idaho
Illinois
Louisiana
Maine
Maryland
Massachusetts
Michigan
Missouri
Nevada
New Hampshire
New Jersey
New York
Ohio
Pennsylvania
Rhode Island
South Carolina
Texas
Utah
Vermont
Virginia
Wyoming
While the variant currently accounts for only a small percentage of cases nationally, its prevalence has been much higher in some European countries, where it represented up to 30% of cases in Denmark, Germany, and the Netherlands. The CDC’s ongoing monitoring is crucial for understanding its growth advantage and potential impact in the U.S.
Symptoms and Severity: What to Expect from Cicada
The symptoms associated with the Cicada variant are largely consistent with those of other currently circulating COVID-19 strains. There is no current evidence to suggest that BA.3.2 causes more severe illness or hospitalizations in countries where it is more widespread. Dr. Adolfo García-Sastre of Mt. Sinai emphasizes that it’s “not a more problematic strain than previous ones.” Pekosz also notes that while it might look “scary on paper,” it hasn’t translated to a significant impact on disease severity in most places.
Common symptoms you might experience if infected with the Cicada variant include:
Runny or stuffy nose
Headache
Fatigue
Sneezing
Sore throat (sometimes reported as “razorblade throat” with newer variants)
Coughing
Changes to the sense of smell or taste
Gastrointestinal issues
These symptoms typically resolve with supportive care, and importantly, the variant remains sensitive to existing COVID antiviral medications.
Expert Outlook and Prevention Strategies
Despite the concerns about its mutations, experts generally do not anticipate the Cicada COVID variant causing a massive surge in the U.S. The WHO has noted that BA.3.2 “has not shown a sustained growth advantage over any other co-circulating variant” and has not overtaken dominant strains like XFG (stratus) or NB.1.8.1 (nimbus). While immune evasion is a possibility, public health officials believe there will still be some “cross-reactivity,” meaning the immune system won’t treat it as entirely foreign. It is considered unlikely to trigger a wave as large or severe as those seen in the early pandemic.
Vaccine Effectiveness and Protection
The significant spike protein changes in BA.3.2 do raise questions about how well current vaccines protect against infection. The 2025-2026 COVID-19 vaccines, designed to target the JN.1 lineage, are effective against severe disease from current dominant strains. While preliminary lab studies indicated these vaccines might be less effective against BA.3.2 infection, more research is ongoing. Experts, including the WHO, expect existing vaccines to continue providing protection against severe disease. Annual vaccine updates, typically reformulated in the summer, help keep pace with evolving variants.
To best protect yourself and your community, the CDC recommends several actionable steps:
Stay Up-to-Date on Vaccinations: Ensure you have received recommended COVID-19 vaccines and boosters, especially if you are over 65, immunocompromised, or have underlying conditions, and haven’t been vaccinated or infected in the past 6-12 months.
Test When Symptomatic: Get tested if you develop symptoms consistent with COVID-19.
Isolate When Sick: Stay home and avoid contact with others if you are ill to prevent further spread.
Improve Ventilation: Enhance air circulation in your home or workplace.
Wear a High-Quality Mask: Consider wearing an N95 or well-fitting mask in high-risk settings or if interacting with vulnerable individuals.
Practice Good Hygiene: Frequently wash hands and clean shared surfaces.
Seek Medical Advice: Contact a healthcare provider if your symptoms worsen or if you experience emergency warning signs like trouble breathing or persistent chest pain.
Frequently Asked Questions
What exactly is the Cicada (BA.3.2) variant and why is it concerning?
The Cicada (BA.3.2) variant is a highly mutated COVID-19 strain, a descendant of the Omicron subvariant BA.3. It was nicknamed “Cicada” due to its slow, largely undetected emergence over time. Experts are concerned because it possesses 70-75 mutations in its spike protein, making it genetically distinct from other circulating variants like JN.1. This extensive mutation profile suggests it may be more capable of evading immunity from previous infections or vaccinations. While it’s under close monitoring, there’s no current evidence it causes more severe illness.
How is the Cicada (BA.3.2) variant being tracked across the U.S.?
The Cicada (BA.3.2) variant is primarily tracked in the U.S. through a robust wastewater surveillance system managed by the CDC’s National Wastewater Surveillance System and Stanford University’s WastewaterSCAN Dashboard. This method allows health officials to detect the variant’s presence and prominence in communities even when individual case reporting is low. As of February 11, 2026, BA.3.2 was detected in wastewater samples from 132 sites across at least 25 U.S. states. It has also been identified through voluntary nose swabs from international travelers.
What precautions should I take against the Cicada variant, and are current vaccines effective?
The precautions against the Cicada variant are similar to those for other COVID-19 strains: stay home if sick, test with symptoms, wear a high-quality mask in crowded settings, and practice good hand hygiene. While the BA.3.2 variant’s significant mutations raise questions about vaccine effectiveness against infection, experts and the WHO anticipate that current COVID-19 vaccines (targeting the JN.1 lineage for 2025-2026) will continue to offer protection against severe disease, hospitalization, and death. Staying up-to-date with your vaccinations and boosters remains the most effective way to reduce serious health risks.
Staying Informed and Prepared
The emergence of the Cicada (BA.3.2) variant is another reminder of the ongoing evolution of the SARS-CoV-2 virus. While its unique mutations warrant vigilant monitoring, current assessments indicate it does not pose a significantly higher risk of severe illness compared to other circulating strains. Public health agencies like the CDC and WHO continue to track its progression, ensuring that the public receives the most accurate and up-to-date guidance. By staying informed, adhering to recommended health precautions, and keeping your vaccinations current, you can play a crucial role in safeguarding your health and community well-being. Continue to monitor official health advisories for the latest information and recommendations.
